S P R A V A T O

What is Spravato?

 

Spravato (Esketamine) is the first prescription

nasal spray taken with an oral antidepressant

for Treatment Resistant Depression (TRD)

and Major Depressive Disorder (MDD).

​

​

Is Spravato covered under

my insurance plan?

 

Yes.  Since Spravato (Esketamine) is an

FDA approved medication, unlike other 

Ketamine products, Spravato is covered by

most insurances for TRD and MDD.

​

​

What is REMS and

Why is it important?

 

REMS is short for Risk Evaluation and

Mitigation Strategy.  Spravato use is guided

by the REMS program to ensure safety.

 

Clients must meet specific criteria to

become a candidate.  This includes failing

2 previous antidepressants.

​

​

What is the route of

administration? 

 

Spravato is administered intranasally.

​

​

How long will I need

to be monitored?

 

There is a minimum of 2 hours of observation

and monitoring of blood pressure at an approved

facility.  This is mandated by the FDA .

​

​

How often do I need Spravato?

 

Spravato is delivered in 3 phases and

they are administered as follows:

​

​

Phase 1: Induction

(Week 1-4)

Twice Weekly 

​

​

Phase 2: Maintenance

(Week 5-8)

Once Weekly 

​

​

Phase 3: Ongoing Treatment

(Week 9+)

Once Every Two Weeks

​

​

What are the possible

side effects of Spravato?

 

Fatigue

Mild Disassociation

Elevated Blood Pressure

Difficulty concentrating and dizziness

Inability to drive or operate machinery

Suicidal thoughts for young adults

​

​

Is Spravato right for me?

 

A comprehensive screening will determine

if you are a good candidate for Spravato.

 

Referral from a medical provider is required

to ensure the REMS patient criteria is met

prior to starting the Spravato medication.

​

​